After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

Spravato is made from esketamine ... your thoughts, feelings, or space and time); and breathing problems (including respiratory arrest). More on mental health: This story was originally featured ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...

Johnson & Johnson's Spravato has been approved to treat a major ... based on individual needs," Mattingly added. "For the first time ever, we now have an option that gives patients freedom." ...

J&J’s Janssen unit – which markets Spravato – said at the time it disagreed with the conclusions, which it claimed were “based on inaccurate assumptions…on the established positive ...

Spravato is classified as a Schedule III controlled substance and is only available through a restricted program called the Spravato REMS. The Food and Drug Administration (FDA) has approved ...

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...

Parkside Psychiatric Hospital in Tulsa has an on-site Spravato outpatient clinic that sees over 20 patients per week. According to Parkside, these patients are seen at least twice a week for the ...

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy treatment for major depressive disorder (MDD) in adults who do not ...

Spravato was first approved back in 2019, but at that time, patients had to use it with an oral antidepressant. Now, it’s been approved to use on its own. It’s for adults with major depressive ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...